The Potential for Clinical Use of Cannabinoids in Treatment of Cardiovascular Diseases

Cardiovascular Therapeutics

Volumn 29, Issue 1, 2011, Pages 17-22

  Durst, Ronen ^a,b   Lotan, Chaim ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arrhythmia; Cannabinoids; Cardiomyopathy; Ischemic heart disease; Preconditioning

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 AG; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACEA; ANANDAMIDE; CANNABIDIOL; CANNABINOID; DEXANABINOL; RIMONABANT; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ARRHYTHMIAS, CARDIAC; CANNABINOIDS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; MYOCARDIAL REPERFUSION INJURY;

EID: 78751489425     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00233.x     Document Type: Review

References (67)

1. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108:1-13.
2. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971;93:217-224.
3. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
5. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
6. Devane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem 1992;35:2065-2069.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
8. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998;359:1-18.
9. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 2006;103:2428-2433.
10. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
11. Howlett AC, Fleming RM. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984;26:532-538.
12. Matsuda LA, Bonner TI, Lolait SJ. Cannabinoid receptors: Which cells, where, how, and why? NIDA Res Monogr 1992;126:48-56.
13. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol 2002;42(11 Suppl):64S-70S.
14. Tashkin DP, Levisman JA, Abbasi AS, Shapiro BJ, Ellis NM. Short-term effects of smoked marihuana on left ventricular function in man. Chest 1977;72:20-26.
15. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002;42(11 Suppl):58S-63S.
16. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805-2809.
17. Gottschalk LA, Aronow WS, Prakash R. Effect of marijuana and placebo-marijuana smoking on psychological state and on psychophysiological cardiovascular functioning in anginal patients. Biol Psychiatry 1977;12:255-266.
18. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004;142:20-26.
19. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995;278:279-283.
20. Garcia N Jr., Jarai Z, Mirshahi F, Kunos G, Sanyal AJ. Systemic and portal hemodynamic effects of anandamide. Am J Physiol Gastrointest Liver Physiol 2001;280:G14-G20.
21. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-1044.
22. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 1996;28:682-686.
23. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 1996;119:107-114.
24. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 1997;29:1204-1210.
25. Gardiner SM, March JE, Kemp PA, Bennett T. Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol 2001;133:445-453.
26. Gardiner SM, March JE, Kemp PA, Bennett T. Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats. Br J Pharmacol 2009;158:1143-1152.
27. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003;138:532-543.
28. Podgoreanu MV, Michelotti GA, Sato Y, Smith MP, Lin S, Morris RW, et al. Differential cardiac gene expression during cardiopulmonary bypass: Ischemia-independent upregulation of proinflammatory genes. J Thorac Cardiovasc Surg 2005;130:330-339.
29. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005;3:221-229.
30. Bell RM, Yellon DM. Molecular mechanisms of preconditioning: Therapeutic implications. Rev Port Cardiol 1998;17(Suppl 2):II49-II61.
31. Schwarz ER, Reffelmann T, Kloner RA. Clinical effects of ischemic preconditioning. Curr Opin Cardiol 1999;14:340-348.
32. Verdouw PD, Gho BC, Duncker DJ. Ischaemic preconditioning: Is it clinically relevant? Eur Heart J 1995;16:1169-1176.
33. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-1918.
34. Smith RM, Lecour S, Sack MN. Innate immunity and cardiac preconditioning: A putative intrinsic cardioprotective program. Cardiovasc Res 2002;55(3):474-482.
35. Cave AC, Horowitz GL, Apstein CS. Can ischemic preconditioning protect against hypoxia-induced damage? Studies of contractile function in isolated perfused rat hearts. J Mol Cell Cardiol 1994;26:1471-1486.
36. Horowitz M. Heat acclimation and cross-tolerance against novel stressors: Genomic-physiological linkage. Prog Brain Res 2007;162:373-392.
37. Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 2001;132:793-796.
38. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998;284:644-650.
39. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 2002;55:619-625.
40. Bouchard JF, Lepicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 2003;72:1859-1870.
41. Philippe L, Jean-François B, Caroline L, Daniel L. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003;139:805-815.
42. Thomas BF, Zhang Y, Brackeen M, Page KM, Mascarella SW, Seltzman HH. Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS J 2006;8:E665-E671.
43. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003;139:805-815.
44. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 2005;146:809-816.
45. Di Filippo C, Rossi F, Rossi S, D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: Involvement of cytokine/chemokines and PMN. J Leukoc Biol 2004;75:453-459.
46. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 2009;46:612-620.
47. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007;21:1788-1800.
48. Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G, et al. Pivotal advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 2007;82:1382-1389.
49. Gabbay E, Avraham Y, Ilan Y, Israeli E, Berry EM. Endocannabinoids and liver disease 2013: Review. Liver Int 2005;25:921-926.
50. Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293:H3602-H3607.
51. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. 2006;103:7895-7900.
52. Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, et al. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull Exp Biol Med 2002;133:122-124.
53. Krylatov AV, Uzhachenko RV, Maslov LN, Ugdyzhekova DS, Bernatskaia NA, Pertwee R, et al. Anandamide and R-(+)-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors. Eksp Klin Farmakol 2002;65:6-9.
54. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, Maslov LN, Mekhoulam R, Pertwee RG, Stephano GB. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 2001;131:523-525.
55. Krylatov AV, Bernatskaia NA, Maslov LN, Pertwee RG, Mechoulam R, Stefano GB, et al. Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors. Ross Fiziol Zh Im I M Sechenova 2002;88:560-567.
56. Ugdyzhekova DS, Bernatskaya NA, Stefano JB, Graier VF, Tam SW, Mekhoulam R. Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: Role of CB(1) and CB(2) receptors. Bull Exp Biol Med 2001;131:251-253.
57. Ugdyzhekova DS, Davydova YG, Maimeskulova LA, Mechoulam R. Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. Bull Exp Biol Med 2000;130:1087-1089.
58. Hajrasouliha AR, Tavakoli S, Ghasemi M, Jabehdar-Maralani P, Sadeghipour H, Ebrahimi F, Dehpour AR. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol 2008;579:246-252.
59. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001;38:2048-2054.
60. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999;96:14136-14141.
61. Wagner JA, Hu K, Karcher J, Bauersachs J, Schafer A, Laser M, et al. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 2003;138:1251-1258.
62. Vollmer RR, Cavero I, Ertel RJ, Solomon TA, Buckley JP. Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol 1974;26:186-192.
63. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997;281:1030-1037.
64. Despres JP. Pleiotropic effects of rimonabant: Clinical implications. Curr Pharm Des 2009;15:553-570.
65. Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: Analysis of pooled RIO study results. J Hypertens 2008;26:357-367.
66. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999;33(1 Pt 2):429-434.
67. Durst R, Goldstein K, Horowitz Y, Baggish A, Gare M, Hasin Y, et al. Hypothyroid dependent myocardial angiotensin receptor trafficking is involved in improved cardiac performance after heat acclimation. Life Sci 2010;86:331-336.